GSK delays Japanese hair-loss treatment launch on Catalent plant problems

Suspected product tampering has put production at a French Catalent ($CTLT) plant on hold--and GlaxoSmithKline ($GSK) is paying the price. The British pharma giant has delayed the launch of hair-loss drug Zagallo in Japan while it searches for another manufacturing site. More from FiercePharma